This study investigates resectable pancreatic cancer. It evaluates an investigational medication combined with chemotherapy.
The study evaluates the safety and effectiveness of this combination treatment. It assesses how well patients tolerate the treatment.
- Who can participate: Adults aged 18 to 75 years with pancreatic cancer may participate. Participants must have an ECOG score of 0 or 1 and an expected survival time of at least 6 months.
- Study details: Participants will receive an investigational medication along with chemotherapy. An inactive substance that looks like the investigational medicine but does not contain any medicine is not used in this study.